Home Cytoskeletal Signaling Microtubule Associated inhibitor Nab-Paclitaxel

research use only

Nab-Paclitaxel Microtubule Polymer stabilizer

Cat.No.E1068

Nab-Paclitaxel is a novel solvent-free paclitaxel in which the binding ratio of paclitaxel to human albumin is approximately 1:9. It is an anti-microtubule drug that promotes microtubule aggregation in tubulin dimers and inhibits microtubule depolymerization to stabilize the microtubule system. Solutions are unstable and should be fresh-prepared.
Nab-Paclitaxel Microtubule Associated inhibitor Chemical Structure

Chemical Structure

Molecular Weight: 853.91（Only for Paclitaxel）

Jump to

Quality Control

Batch: Purity: 99.18%
99.18

Solubility

In vitro
Batch:

Water : 3 mg/mL

DMSO : Insoluble
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : Insoluble

Molarity Calculator

Mass Concentration Volume Molecular Weight
Dilution Calculator Molecular Weight Calculator

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg
g
μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO
%
% Tween 80
% ddH2O
% DMSO
+
%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight 853.91（Only for Paclitaxel） Formula

C47H51NO14

 Storage (From the date of receipt) Store at room temperature, 3 years
CAS No. -- Storage of Stock Solutions Solutions are unstable. Prepare fresh or purchase small, pre-packaged sizes. Repackage upon receipt.

Read more about storage stability

Mechanism of Action

In vitro

Treating human pancreatic ductal adenocarcinoma cells first with gemcitabine followed by Nab-Paclitaxel at 48 hours is found to have the greatest inhibition of cell growth.
In vivo

In mice with human pancreatic cancer xenografts, nab-paclitaxel alone and in combination with gemcitabine deplete the desmoplastic stroma. The intratumoral concentration of gemcitabine is increased by 2.8-fold in mice receiving nab-paclitaxel plus gemcitabine versus those receiving gemcitabine alone.
References
  • [4] https://pubmed.ncbi.nlm.nih.gov/21969517/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2026-09-04)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT06096844 RECRUITING
Advanced Lung Non-Small Cell Carcinoma; Stage IIIB Lung Cancer AJCC v8; Stage IIIC Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8
National Cancer Institute (NCI)
 2024-07-19 PHASE3
NCT07060807 RECRUITING
Breast Neoplasms
Merck Sharp & Dohme LLC
 2025-07-21 PHASE3
NCT04198766 RECRUITING
Solid Tumor; Non-Small Cell Lung Cancer; Head and Neck Cancer; Melanoma; Gastric Cancer; Renal Cell Carcinoma; Urothelial Carcinoma; Resectable Non-Small-Cell Lung Cancer
Inhibrx Biosciences, Inc
 2019-12-10 PHASE1; PHASE2
NCT06714604 RECRUITING
Locally Advanced Pancreatic Adenocarcinoma; Borderline Resectable Pancreatic Carcinoma; Pancreas Cancer; Neoadjuvant Chemotherapy; Surgery; Pancreatectomy
Sahlgrenska University Hospital
 2023-10-18 PHASE3
NCT07629817 RECRUITING
Esophageal Squamous Cell Carcinoma
Henan Cancer Hospital
 2026-06-16 PHASE3
NCT06731907 RECRUITING
Non-small Cell Lung Cancer
Merck Sharp & Dohme LLC
 2025-03-30 PHASE2

Read more about Clinical Trials

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Signaling Pathway Map